New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:33 EDTCBMGCellular Biomedicine completes enrollment in ReJoin Phase IIb clinical trial
Cellular Biomedicine has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell-based therapy ReJoin for Knee Osteoarthritis. The Phase I/IIa clinical trial for this therapy was completed in 4Q13. The primary endpoints for this trial are knee-related pain, stiffness and function.
News For CBMG From The Last 14 Days
Check below for free stories on CBMG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
09:35 EDTCBMGCellular Biomedicine reports Q2 EPS (85c) vs. (44c) last year
As of June 30, the company had $13.6M in cash and cash equivalents.
August 12, 2014
08:23 EDTCBMGCellular Biomedicine completes patient treatment in ReJoin Phase IIb trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use